Isofol Medical AB (publ) announced that the board of Isofol has decided to appoint Thomas Andersson as CEO of the company from February 28, 2023. As a consequence of this decision, the current CEO, Ulf Jungnelius, is resigning and is now being dismissed from his position. Thomas Andersson (b. 1952) has long experience from leading positions in the pharmaceutical industry, including as CEO of Spectracure, Senior Advisor at Karolinska Institutet Innovations AB, Investment Manager at Karolinska Development AB, CEO of Lund University Bioscience AB, Head of Cell Therapy at Bavarian Nordic AS and CEO of Annexin Pharmaceuticals AB.

He has been part of the founding of more than 15 companies, held over 20 board assignments and is currently Senior Advisor Business Development at Oslo Cancer Cluster Incubator as well as board member of Kongsberg Beam Technology AS, Thepler AS and Skogsmöllan AB. Thomas Andersson has a PhD in physical chemistry from Lund University.